Close
Almac
Achema middle east

Don’t be left behind by the latest ISO 9001 Revision

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

According to ISO annual survey published in November 2017, 1,025,761 certificates were issued based on ISO 9001:2008 but only 80,596 certificates based on the new ISO 9001:2015 during 2016.

In spite of the 3-year transition period – starting from 31 Dec 201 – for achieving the ISO 9001:2015 certification, there are still numerous organizations which have yet to adapt to the new procedures for staying competitive in the challenging global market.

ISO-certified companies need to undergo the certification process to be ready for September 2018: this means there are only 9months left to update Quality Management Systems to the latest version of ISO 9001.

These changes have an impact on weighing devices and weighing processes, as weight measurements are a critical process step which can significantly affect quality.

METTLER TOLEDO’s white paper highlights the changes in the revised standard of ISO 9001:2015and what this means for weighing processes, and describes the timeline associated with transition to the new version.

Additionally, it helps the reader to understand the new approach focused on risk-based thinking and its effect on weighing processes. These recommendations enable business as well as other sectors to meet the requirements for being more productive and ensuring customer satisfaction at the same time.

Register to download the free white paper explaining the impact of ISO 9001:2015 on Weighing Processes

About METTLER TOLEDO
METTLER TOLEDO is a leading global supplier of precision instruments and services. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. METTLER TOLEDO also holds top-three market positions in several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection and other end-of-line inspection systems used in production and packaging and holds a leading position in certain process analytics applications. Additional information about METTLER TOLEDO can be found at www.mt.com

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »